Loading candles…
Venus Remedies Ltd, incorporated in 1989, is a research-based pharmaceutical company operating in the pharmaceutical and healthcare industries. The company focuses on developing and manufacturing therapeutic solutions primarily within critical care segments, including treatments for multi-drug resistant bacteria. Its product portfolio spans anti-infectives such as antibiotics, oncology, neurology, pain management, and skin and wound care. Venus Remedies serves both domestic and international markets through its manufacturing facilities. The company includes the Venus Medicine Research Centre (VMRC), its research division accredited by the Department of Scientific and Industrial Research (DSIR). No information on founders, key management, listings, or notable projects was provided.
This page is a live market overview for VENUS REMEDIES LIMITED (VENUSREM) on the NSE. As a listed security, VENUS REMEDIES LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for VENUSREM before placing trades on tick2trade.
As of the latest feed, VENUSREM last traded at ₹1,644 on NSE, up ₹32.5 (2.02%) from the previous close of ₹1,611.5. Today's session range is ₹1,603.4 – ₹1,679.3, against a 52-week band of ₹424 – ₹2,044.3. Traded volume today stands at 33.37K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for VENUSREM in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether VENUSREM is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for VENUS REMEDIES LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in VENUSREM. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated VENUSREM option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters | 20 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026, dividend and Agenda pertaining to ensuing Annual General Meeting of the co… | 26 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and any other item with the permission of chair. | 29 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and any other item with the permission of chair. | 19 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 10 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 1 Aug 2025 |
| Other | To consider other business ma1. To consider and approve Notice of 36th Annual General Meeting.2. To consider and approve Board s Report for Financial Year 20… | 8 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 26 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.